CUPERTINO, Calif., Sept. 15, 2021 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, Dr. Norman Sussman, Chief Medical Officer, and Dr. WeiQi Lin, Executive Vice President of R&D, will be participating in a fireside chat hosted by Francois Brisebois, Managing Director, Senior […]
CUPERTINO, Calif., Sept. 7, 2021 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President, CEO, Michael H. Arenberg, Chief Financial Officer, Dr. Norman Sussman, Chief Medical Officer and Dr. WeiQi Lin, Executive Vice President of R&D will be participating in a fireside chat hosted by Ed Arce of H.C. Wainwright, at the
Earnings Call and Webcast Today, July 29th at 4:30 p.m. ET CUPERTINO, Calif., July 29, 2021 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2021 and provided a corporate update. Q2 2021 Accomplishments: We expanded the number of U.S. clinical trial sites to 26 in the Phase
CUPERTINO, Calif., July 22, 2021 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will report its second quarter 2021 financial results and host a conference call after the market close on Thursday, July 29, 2021. Thursday, July 29 @ 4:30pm Eastern Time / 1:30 p.m. Pacific Time Toll Free: 877-407-0784 International: 201-689-8560 Conference ID: 13721980 Webcast:
CUPERTINO, Calif., July 14, 2021 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it will present at the Epigenetic Therapeutic Targets Summit, being held virtually July 13-15, 2021. Our President and Chief Executive Officer, James E. Brown, D.V.M., will discuss the mechanism of action of our lead drug candidate and epigenetic regulator (DUR-928), the previously reported
DURECT Corporation to Present at the 2021 Epigenetic Therapeutic Targets Virtual Summit Read More »
New Data Further Supports DUR-928’s Potential in Acute and Chronic as well as Moderate and Severe Liver Disease CUPERTINO, Calif., June 23, 2021 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced the presentation of additional clinical data from a DUR-928 Phase 1b trial in non-alcoholic steatohepatitis (NASH) and a Phase 1 trial in subjects with hepatic
CUPERTINO, Calif., June 9, 2021 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it will present two posters at the 2021 International Liver Conference (EASL) to be held virtually June 23-26, 2021. The first poster will discuss additional efficacy signals from a Phase 1b clinical study of orally administered DUR-928 in nonalcoholic steatohepatitis (NASH) patients. Previously reported
Webcast of Earnings Call Today, May 4th at 4:30 p.m. ET CUPERTINO, Calif., May 4, 2021 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2021 and provided a corporate update. Q1 2021 Accomplishments: Initiated patient dosing in the Phase 2b AHFIRM clinical study of DUR-928 in severe
DURECT Corporation Announces First Quarter 2021 Financial Results and Update of Programs Read More »
CUPERTINO, Calif., April 27, 2021 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2021 financial results and host a conference call after the market close on Tuesday, May 4, 2021. Tuesday, May 4 @ 4:30pm Eastern Time / 1:30 p.m. Pacific Time Toll Free: 877-407-0784 International: 201-689-8560 Conference ID: 13718713 Webcast:
— DUR-928 is an inhibitor of DNA methyltransferases (DNMTs) regulating expression of genes involved in cell survival, inflammation and lipid biosynthesis — Mechanism of action supports development of DUR-928 for the treatment of multiple acute organ injury and chronic diseases — Published in peer reviewed Journal of Lipid Research CUPERTINO, Calif., March 9, 2021 /PRNewswire/
DURECT Corporation Announces Publication of DUR-928’s Mechanism of Action Read More »
